High-quality peptides, backed by science

Power BioLabs Peptides

Peptide & compound research overview • educational content

Retatrutide (LY3437943)

Status: Investigational – Not yet FDA-approved (multiple Phase 3 trials ongoing as of Jan 2026).

Triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors to regulate metabolism, appetite, and energy balance: GLP-1 reduces appetite/slows gastric emptying/promotes satiety; GIP enhances insulin secretion/glucose control; glucagon increases energy expenditure/promotes fat breakdown. This multi-target approach differentiates it from single or dual agonists, potentially offering enhanced weight reduction and metabolic improvements. Administered as once-weekly subcutaneous injection; primarily investigated for obesity (including overweight with related conditions), type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and related complications like knee osteoarthritis pain.

Key Benefits

• Significant weight loss — supports large, clinically meaningful reductions (often among the highest in class), helping achieve ≥10–15% or greater body weight loss when combined with diet and exercise.

• Metabolic health improvements — lowers fasting glucose/HbA1c, improves lipid profiles (lower triglycerides), reduces waist circumference, lowers blood pressure, decreases liver fat content.

• Additional advantages — reduced hunger/cravings, better portion control, increased energy/mobility, improved mood/confidence, enhanced physical function (e.g., relief from weight-related joint pain like knee OA).

• Broader potential — may benefit obesity-linked conditions including cardiovascular risks and liver health due to multi-receptor action.

Effects are dose-dependent (higher doses yield greater results) and best achieved with lifestyle changes. Side effects mainly gastrointestinal (nausea, vomiting, diarrhea, constipation) — typically mild/moderate, dose-related, improve over time. Transient heart rate increase may occur but often declines. No major unexpected safety concerns identified to date, though long-term data still building.

Retatrutide Dosing Guidelines (Trial-Based Titration – No Approved Dose Yet)

Low-and-slow escalation to minimize GI side effects. Based on Phase 2/3 trial protocols (e.g., starting low, targeting up to 12 mg weekly for max efficacy):

Weeks 1–4
• Weekly dose: 1–2 mg
• Notes: Starting / tolerance phase; common initiation

Weeks 5–8
• Weekly dose: 4 mg
• Notes: Escalation step

Weeks 9+
• Weekly dose: 8–12 mg
• Notes: Maintenance / target range (12 mg showed highest weight loss in trials)

Tirzepatide (Mounjaro / Zepbound)

Status: FDA-approved for type 2 diabetes (Mounjaro), chronic weight management in obesity/overweight with conditions, and obstructive sleep apnea (Zepbound).

Dual hormone receptor agonist targeting GLP-1 and GIP receptors: GLP-1 suppresses appetite/slows digestion/promotes satiety/enhances insulin secretion; GIP boosts insulin response/improves glucose control/supports fat metabolism. Dual action provides more potent weight loss/glycemic control than single GLP-1 agonists. Administered as once-weekly subcutaneous injection; used off-label in some cases and shows benefits in prediabetes, cardiometabolic health, HFpEF, kidney function.

Key Benefits

• Significant weight loss — average reductions up to ~20–23% body weight (or more) over 72 weeks at higher doses (e.g., 15 mg), sustained with lifestyle; many achieve ≥15–20% loss, primarily fat mass while preserving lean muscle.

• Glycemic control — reduces HbA1c by up to ~2–2.5%, lowers fasting glucose, decreases progression to type 2 diabetes (~94% risk reduction in prediabetes over extended periods).

• Metabolic/cardiometabolic improvements — lowers blood pressure, improves lipids (reduced triglycerides/total/LDL, increased HDL), decreases waist/visceral fat/inflammation/cardiovascular risk; benefits extend to sleep apnea (reduced AHI), HFpEF, kidney function.

• Other advantages — reduced hunger/cravings, better portion control/eating habits, increased satiety/fullness, higher energy/mobility, improved mood/confidence, enhanced physical function (less joint strain from weight loss); many maintain substantial loss post-discontinuation in real-world data.

Effects dose-dependent (higher 10–15 mg yield greater results) and best with lifestyle changes. Side effects primarily gastrointestinal (nausea, vomiting, diarrhea, constipation, abdominal pain) — mild/moderate, dose-related, improve over time/escalation. Rare serious risks (pancreatitis, gallbladder, thyroid concerns — monitoring recommended). Hypoglycemia low without insulin/sulfonylureas. Overall well-tolerated; discontinuation rates ~4–10% in studies; long-term safety aligns with GLP-1 class.

Tirzepatide — FDA-Approved Dosing (Once Weekly)

Weeks 1–4
• Weekly dose: 2.5 mg
• Notes: Initiation / tolerance phase (not for glycemic control)

Weeks 5+
• Weekly dose: 5 mg
• Notes: Starting maintenance dose

As needed (every ≥4 weeks)
• Dose increase: +2.5 mg increments
• Notes: Titrate based on response and tolerance, up to 15 mg maximum

BPC-157 / TB-500 Blend

Status: Experimental research peptides – Not approved for human use; sold "for research only."

Combination of BPC-157 (pentadecapeptide from gastric protein; promotes healing in tendons/ligaments/muscles/bones/GI tract, angiogenesis, collagen production, anti-inflammation, tissue protection) and TB-500 (synthetic thymosin beta-4 fragment; systemic effects on cell migration, actin regulation, inflammation reduction, flexibility, broad regeneration). Synergistic: BPC-157 more targeted/local (injuries, joints, gut); TB-500 systemic (circulation, muscle recovery). Administered via subcutaneous injection; explored in athletic recovery, injury rehab, post-surgical, chronic joint/muscle issues.

Key Benefits

• Accelerated tissue repair & healing — speeds musculoskeletal injuries (tendons/ligaments/muscles), fractures, strains; improves structural/functional outcomes in models.

• Reduced inflammation & pain — anti-inflammatory effects for chronic pain, joint issues (tendonitis, arthritis-like), post-injury swelling.

• Improved mobility & flexibility — enhanced circulation, collagen deposition, remodeling for better range of motion/resilience.

• Synergistic recovery support — localized + systemic effects for faster post-workout/surgery recovery, reduced scarring, immune modulation, physical resilience.

• Other reported advantages — gut health (BPC-157 strength), wound healing, quicker return to activity; anecdotal relief from nagging injuries (elbow/shoulder tendonitis).

Effects dose-dependent/combined with rest/therapy/lifestyle. Evidence from animal studies, in-vitro, user experiences (not large human trials). Common side effects mild: injection-site irritation/redness/soreness, transient fatigue/mild nausea/dizziness/headache, occasional soreness during healing. Serious risks low in preclinical; long-term human safety unknown; concerns include immune modulation, sourcing quality (contamination/purity). Not associated with major toxicity in animal data.

BPC-157 / TB-500 Blend — Typical Research Protocols

BPC-157
• Typical dose: 200–500 mcg (commonly 250–500 mcg)
• Frequency: 1–2× daily
• Notes: Often administered near injury site; cycles 4–8 weeks

TB-500
• Typical dose: 2–5 mg loading, then 2–2.5 mg maintenance
• Frequency:
– Loading: 2× weekly
– Maintenance: 1–2× weekly

Blend (equal parts)
• Typical dose: 500–1000 mcg total daily
• Frequency: Once daily or 5 days on / 2 days off
• Notes: Common 4–8 week cycles

Thymosin Alpha -1

Status: Approved in over 35 countries (hepatitis B/C, immune enhancer in infections/cancer); limited U.S. indications; clinically established immunomodulator.

Synthetic peptide mimicking natural thymic hormone; enhances/restores/balances immune function: stimulates T-cell differentiation/maturation, boosts thymic output/NK cell activity, modulates dendritic cells/macrophages/cytokines, provides anti-inflammatory/antioxidant effects without overstimulation (useful in deficient or dysregulated states). Administered via subcutaneous injection; used clinically for decades in immune support contexts.

Key Benefits

• Immune enhancement & restoration — strengthens defenses against infections (viral/bacterial/fungal), improves vaccine responses (especially older/immunocompromised), restores balance in suppression/dysregulation.

• Support for chronic/severe infections — adjunct in hepatitis B/C, HIV, sepsis (improved survival), severe acute pancreatitis (reduced inflammation/infections), post-viral conditions; may reduce severity in acute infections.

• Oncology adjunct — enhances immune response in cancer (lung/colon/breast), combined with chemo/immunotherapy to improve efficacy/reduce immunosuppression/better outcomes.

• Autoimmune & inflammatory conditions — modulates overactive immunity in RA, lupus, IBD; dampens excessive inflammation while preserving protection.

• Other advantages — benefits in aging immunosenescence (improved resilience), chronic fatigue, Lyme support, severe critical illness (reduced organ dysfunction), vaccine adjuvant (influenza/COVID boosters); users report fewer infections, better energy/immune stability.

Effects generally dose-dependent; best under medical guidance with monitoring. Very well-tolerated with strong safety profile from decades of use. Common side effects mild: injection-site reactions (redness/swelling/irritation), transient fatigue/flu-like symptoms/mild fever/nausea/muscle aches/headache. Serious adverse events rare; low toxicity/no major organ risks; rare autoimmune flare in susceptible (due to modulation — monitor). Long-term use safe in approved indications.

Thymosin Alpha-1 — Clinical / Approved Contexts

Standard dose
• Dose: 1.6 mg
• Frequency: 2× weekly
• Notes: Common for chronic protocols (e.g., hepatitis; 6–12 months)

Higher dosing
• Dose: 3.2–6.4 mg
• Frequency: 2–3× weekly or short courses
• Notes: Higher dosing for acute or adjunct use; <40 kg often adjusted to ~40 mcg/kg

KLOW 80 Blend (GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg)

Status: Experimental research blend – Not approved for human use.

Multi-peptide complex: GHK-Cu (copper-binding tripeptide; collagen synthesis, angiogenesis, wound healing, ECM remodeling, skin rejuvenation, anti-aging/gene expression); BPC-157 (tendon/ligament/muscle/gut repair, anti-inflammation); TB-500 (actin regulation, cell migration, flexibility, systemic regeneration); KPV (alpha-MSH-derived tripeptide; potent anti-inflammatory/immunomodulatory via NF-κB/cytokine modulation, gut/skin immune balance). Administered via subcutaneous injection; popular in regenerative/biohacking for comprehensive healing/inflammation control.

Key Benefits

• Accelerated tissue repair & recovery — supports musculoskeletal injuries/wounds/post-workout/surgery healing, connective tissue remodeling via complementary pathways (angiogenesis, collagen, cell migration).

• Reduced inflammation & pain — strong synergy (especially KPV/BPC-157) lowers systemic markers (TNF-alpha/IL-6), calms gut/skin/immune responses, eases chronic/joint pain/inflammatory conditions.

• Improved skin, hair, & aesthetic health — GHK-Cu drives collagen/elastin, rejuvenation, reduced scarring; users report better glow/hair health.

• Gut & immune balance — BPC-157 + KPV enhance lining integrity, reduce gut inflammation, support modulation without overstimulation.

• Other advantages — enhanced energy/mobility, resilience, potential mitochondrial support, holistic regeneration (deeper + surface benefits); often called "upgrade" from simpler blends.

Effects synergistic/dose-dependent; protocols often daily/frequent over 8–16 weeks with rest/nutrition/therapy. Common side effects mild: injection-site reactions, transient fatigue/headaches/flu-like, occasional skin breakouts (GHK-Cu/detox response), mild nausea/soreness in healing areas. Serious risks low in preclinical/component data; long-term human safety largely unknown (limited trials); sourcing quality critical (contamination/purity issues), potential immune modulation effects/interactions. Blue/purple tint in vials normal (GHK-Cu copper).

KLOW 80 Blend — Typical Anecdotal Dosing (80 mg vial)

Weeks 1–2
• Daily volume: 0.075 mL (≈2 mg total blend)
• Approximate per component:
– GHK-Cu ≈1.25 mg
– BPC-157 / TB-500 / KPV ≈250 mcg each
• Notes: Low start to assess tolerance

Weeks 3+
• Daily volume: 0.15–0.3 mL (≈4–8 mg total blend)
• Approximate per component:
– GHK-Cu ≈2.5–5 mg
– BPC-157 / TB-500 / KPV ≈500 mcg–1 mg
• Notes: Maintenance; often 5 days on / 2 days off; 4–8 week cycles

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper)

Status: Widely used in over-the-counter skincare/cosmetics (topical); injectable forms experimental – Not approved for systemic use.

Naturally occurring tripeptide bound to copper; declines with age; acts as regenerative/protective signaling molecule influencing gene expression (regulates thousands), tissue remodeling, inflammation modulation without overstimulation. Facilitates copper for enzyme activity/repair; stimulates collagen/elastin/glycosaminoglycans; enhances angiogenesis/fibroblast/ECM; antioxidant/anti-inflammatory/cell-protective (suppresses NF-κB, DNA repair, proteasome activation). Available topical (creams/serums) or injectable (SC); delivery affects absorption/systemic reach.

Key Benefits

• Skin rejuvenation & anti-aging — boosts collagen/elastin, improves firmness/elasticity/thickness/texture; reduces fine lines/wrinkles/sagging/photodamage/age spots/hyperpigmentation; enhances clarity/glow.

• Wound healing & tissue repair — accelerates wounds/scars/damaged tissues (skin/connective/lung/liver); supports remodeling for better structure/function.

• Hair growth & scalp health — promotes follicle enlargement/thickness/growth, reduced loss in studies.

• Anti-inflammatory & protective effects — reduces inflammation/oxidative stress/aging markers; broader benefits like lung protection, anti-cancer signaling, cellular resilience.

• Other advantages — improved skin barrier, reduced mottled pigmentation, enhanced nerve/blood vessel outgrowth, potential systemic support for healthier aging (gene-level youthful patterns restoration).

Effects subtle/cumulative (weeks/months), dose-dependent, enhanced with consistent use/skincare/lifestyle. Favorable safety profile with decades in cosmetics/wound care; naturally occurring/non-toxic/well-tolerated at low concentrations. Topical side effects mild/temporary: skin irritation/redness/sensitivity/dryness (initial/strong formulations). Injectable: mild irritation/headache/fatigue/dizziness/nausea (rare); copper toxicity concern with excessive use (unlikely standard doses; avoid in copper disorders like Wilson's). Long-term injectable data limited; potential immunogenicity/injection reactions.

GHK-Cu — Injectable Anecdotal Use

• Typical dose: 1–2 mg daily
• Frequency: Daily
• Notes: Cycles commonly 4–8 weeks on / off

Melanotan II (MT-2)

Status: Experimental – Not approved anywhere; high-risk unregulated compound.

Synthetic cyclic heptapeptide analog of alpha-MSH; non-selective melanocortin receptor agonist (primarily MC1R for pigmentation; also MC3R/MC4R/others) stimulates melanin for tanning. Enhanced stability/brain permeability/broader effects vs natural α-MSH. Administered via subcutaneous injection (or nasal spray less common); common in tanning/performance communities.

Key Benefits

• Rapid skin tanning — increases eumelanin for darker/longer-lasting tan with minimal UV; noticeable darkening in days/weeks; potential reduced sunburn in some contexts.

• Erectile function & sexual arousal — promotes spontaneous erections/increased libido/desire in men/women; originally researched for ED with efficacy in studies.

• Appetite suppression & other effects — curbs hunger, supports weight management indirectly; influences energy/compulsive behaviors via MC4R.

• Other reported advantages — potential photoprotection (controversial), reduced sun damage motivation, mood/energy changes; explored for melanocortin roles (inflammation/neuroprotection).

Effects dose-dependent/cumulative (loading/maintenance); often with limited sun for optimal tanning. Range of side effects from non-selective activation: frequent/mild nausea/vomiting/facial flushing/appetite loss/headache/fatigue/yawning; sexual spontaneous/prolonged erections/increased libido; skin darkening/new moles/freckles (reversible but concerning); other dizziness/muscle pain/abdominal cramps/anxiety/somnolence (higher doses). Serious: mole darkening/dysplastic naevi, potential melanoma/skin cancer links (mixed evidence; some see protection via less UV but experts warn); rare renal/vascular/stroke/anaphylaxis/vision/brain swelling. Long-term unknowns; limited trials; unregulated sourcing risks (contamination/purity). Widely regarded high-risk by authorities.

Melanotan II (MT-2) — Anecdotal Protocol

Loading phase
• Dose: 0.25–0.5 mg daily
• Notes: Continue until desired pigmentation achieved

Maintenance
• Dose: 0.5–1 mg
• Frequency: 1–2× weekly

CJC-1295 (± DAC)

Status: Experimental research peptide – Not approved.

Synthetic GHRH analog stimulating pulsatile endogenous GH release from pituitary, elevating IGF-1 for anabolic processes (protein synthesis/cell repair/metabolism) without direct GH injection. Variants: without DAC (short half-life ~30 min–hours; mimics natural pulses; multiple daily doses or stacked); with DAC (extended half-life ~6–8 days via albumin binding; less frequent but continuous elevation/less "natural"). Administered SC; popular in anti-aging/performance/regenerative (often stacked with Ipamorelin).

Key Benefits

• Increased GH & IGF-1 — elevates GH significantly/sustains IGF-1 for days/weeks; supports anabolic environment.

• Muscle growth & strength — lean mass gains, improved strength/protein synthesis.

• Fat loss & body composition — enhances metabolism/reduces fat (visceral); better composition.

• Improved recovery & repair — faster healing/injuries/exercise; reduced downtime; tissue repair.

• Better sleep quality — deeper/restorative (nighttime dosing benefit).

• Anti-aging & wellness — energy boost, skin elasticity/collagen, reduced wrinkles, hair/nails strength, cognitive/mental clarity, immune/metabolic support; joint/bone density.

Effects dose-dependent/cumulative; amplified stacked/with lifestyle. Side effects mild/transient: injection-site reactions, flushing/warmth/tingling/headache, water retention/edema (mild/resolves), fatigue/dizziness/nausea (early/higher doses). DAC variant: prolonged effects (sustained retention/HR elevation in some); viewed riskier/less physiologic. Serious rare: hormonal imbalances, theoretical GH risks (cell growth/cancer in high contexts — limited evidence), cardiac in sensitive. No major toxicity in data; long-term trials sparse.

CJC-1295 — Anecdotal Dosing

Without DAC
• Dose: 100–300 mcg
• Frequency: 1–3× daily

With DAC
• Dose: 1–2 mg
• Frequency: Once weekly

MOTS-c

Status: Experimental mitochondrial-derived peptide – Not approved.

16-amino-acid protein from mtDNA; metabolic regulator/exercise mimetic activating AMPK (energy sensor promoting glucose uptake/fat oxidation/mitochondrial biogenesis); influences CK2-PTEN-AKT-FOXO1 for muscle/metabolic effects. Levels rise with exercise/decline with age/obesity/T2D/metabolic stress; exogenous mimics/restores benefits for energy homeostasis/insulin sensitivity/resilience.

Key Benefits

• Exercise-like metabolic effects — mimics activity: AMPK boost, glucose uptake/insulin sensitivity (insulin-independent), mitochondrial function/biogenesis, efficient energy/fat metabolism.

• Improved insulin sensitivity & glucose control — prevents/reverses resistance, lowers fasting glucose, improves homeostasis; potential in T2D (reduced pancreatic senescence, better diabetic heart).

• Fat loss & body composition — reduces visceral fat, prevents diet-induced obesity/weight gain; lowers myostatin to preserve lean mass during loss/high-fat diets.

• Muscle preservation & performance — protects against age/obesity sarcopenia, enhances endurance/performance, supports recovery/stress adaptation.

• Anti-aging & longevity support — counters age-related metabolic decline, reduces inflammation/oxidative stress, promotes cellular resilience; correlates with better muscle power in humans.

• Other advantages — potential cardioprotective (diabetic cardiomyopathy/NASH), anti-inflammatory, cognitive/sleep benefits, protection against metabolic diseases (obesity-linked).

Effects cumulative/enhanced by exercise/diet; synergistic with lifestyle. Appears well-tolerated in limited data; favorable preclinical profile/no major toxicity in animals. Reported side effects mild/transient (user reports): injection-site irritation, increased heart rate/palpitations, insomnia, fever, fatigue, occasional nausea/headache/flu-like. Long-term human safety incomplete/unknown (sparse controlled trials); concerns in metabolic/cardiac conditions. Analog (CB4211) showed safety in early Phase 1 before halted.

MOTS-c — Anecdotal Use

• Typical dose: 5–10 mg weekly
• Notes: Often split into multiple injections per week

Ipamorelin

Status: Experimental research peptide – Not approved (compounding restricted in many cases).

Synthetic pentapeptide/selective growth hormone secretagogue/ghrelin mimetic binding GHS-R1a on pituitary; stimulates pulsatile endogenous GH release more naturally/selectively than older GHRPs (minimal cortisol/prolactin/appetite impact). Elevates GH/IGF-1 for anabolic/regenerative processes. Administered SC; popular in anti-aging/performance/body comp/recovery (often stacked with CJC-1295).

Key Benefits

• Muscle growth & strength — lean mass gains, protein synthesis, improved strength via GH/IGF-1.

• Fat loss & body composition — enhances lipolysis/reduces fat (visceral); supports metabolism without strong appetite increase.

• Improved recovery & repair — faster healing/workouts/injuries; reduced downtime/tissue repair.

• Better sleep quality — enhances deep/restorative sleep (nighttime dosing).

• Anti-aging & wellness — increased energy/vitality, skin elasticity/collagen, bone/joint strength, potential cognitive benefits, metabolic support.

• Other advantages — minimal side profile vs other GHRPs; preserves natural GH pulses; indirect bone density/immune/cardiovascular support.

Effects dose-dependent/cumulative; amplified stacked/lifestyle. Regarded as one of safer/better-tolerated GHS; low hormonal disruption (no significant cortisol/prolactin/hunger). Common side effects mild/transient: injection-site reactions, headaches/flushing/dizziness/light fatigue, water retention (mild/resolves), occasional joint pain/numbness/tingling (rare). Serious low in data; long-term studies limited; theoretical GH-related issues (insulin sensitivity/cell growth in high-risk contexts — sparse evidence). No major organ toxicity.

Ipamorelin — Anecdotal Dosing

• Dose: 100–300 mcg
• Frequency: 1–3× daily
• Notes: Often taken at bedtime; commonly stacked

Sermorelin

Status: Available via prescription compounding (legacy GHRH analog); no active branded product (original Geref discontinued commercially ~2008).

Synthetic 29-amino-acid analog of GHRH; stimulates pulsatile natural endogenous GH release from pituitary, elevating IGF-1; mimics physiological secretion more closely than direct hGH (preserves feedback mechanisms/pituitary function). Administered SC; explored in anti-aging/wellness/performance/hormone optimization (often off-label in adults).

Key Benefits

• Increased natural GH & IGF-1 — boosts production (often 2–10x baseline pulses); supports anabolic processes without exogenous overload.

• Improved body composition — lean muscle/strength/protein synthesis gains; fat loss (visceral/abdominal); better metabolism.

• Enhanced recovery & repair — faster healing/exercise/injuries; reduced soreness; tissue/joint/bone regeneration.

• Better sleep & energy — deeper/restorative sleep (nighttime dosing); increased daytime vitality/reduced fatigue; mood/cognitive clarity.

• Anti-aging & vitality — skin elasticity/collagen, hair/nail strength, immune function, libido/sexual health, metabolic resilience in aging adults.

• Other advantages — helps age-related GH decline symptoms (energy/muscle loss/fat gain); viewed "safer" GH booster vs direct hGH/other secretagogues.

Effects dose-dependent/cumulative; enhanced lifestyle. Generally well-tolerated/favorable profile from historical/compounding data. Common side effects mild/transient: injection-site reactions, flushing/headache/dizziness/light nausea, mild water retention/joint discomfort (rare), occasional fatigue/tingling. Serious low; avoids many direct GH issues (less insulin resistance/no major prolactin/cortisol spikes). Long-term adult data limited (original pediatric/diagnostic); no major toxicity signals. Monitoring (IGF-1/thyroid) recommended.

Power BioLabs • Educational resources only • Updated 2026-01-31

Sermorelin — Compounded / Prescription Use

• Dose: 100–300 mcg
• Frequency: Nightly
• Notes: Commonly administered at bedtime on an empty stomach

Tesamorelin

Status: FDA-approved for reduction of excess abdominal (visceral) fat in HIV-associated lipodystrophy. Research and off-label use explored in metabolic health, fat redistribution, and GH optimization contexts.

Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH). It stimulates the pituitary gland to increase endogenous pulsatile growth hormone (GH) release, leading to downstream increases in IGF-1. Unlike direct HGH administration, Tesamorelin preserves natural feedback mechanisms and physiologic secretion patterns.

It has been clinically shown to selectively reduce visceral adipose tissue (VAT) without significantly affecting subcutaneous fat, making it distinct from other GH secretagogues.

Key Benefits

• Reduction of visceral (abdominal) fat
• Improved body composition without muscle loss
• Increased endogenous GH and IGF-1
• Improved lipid profiles and metabolic markers
• Potential cognitive, energy, and recovery benefits
• Preserves natural GH pulsatility (unlike exogenous HGH)

Standard Dosage Recommendations (Clinical & Research Context)

FDA-Approved Clinical Dose (Egrifta SV):
• Dose: 2 mg
• Frequency: Once daily
• Route: Subcutaneous injection
• Timing: Typically administered at the same time each day

This is the standard and most widely referenced dose in clinical trials and FDA labeling.

Common Research / Off-Label Protocols

• 1–2 mg daily, subcutaneous
• Some protocols split dosing (e.g., 1 mg AM / 1 mg PM), though once-daily dosing is most common
• Cycles commonly range 12–26 weeks, followed by reassessment
• Often stacked with lifestyle interventions (diet, resistance training, sleep optimization)

Research Disclaimer: Content is educational and intended for scientific discussion only. Nothing on this page is medical advice, dosing guidance, or instructions for human use. Many compounds discussed are investigational and may be unlawful to sell for human consumption. Consult a licensed clinician for medical decisions.